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Cardiac &hernia is associated with increased morbidity and 
mortality, but most cardiac ischemia is asymptomatic. In 
multiple reports eparately evaluating relatively small num- 
bers of patients with myocardial infarction, unstable angina 
or chronic stable angina, &ymptomatic is hemia detected by 
ambulatory electrocardiographic (ECG) monitoring has been 
linked to adverse outcome (l-18). The influence ofambula- 
tory ECG ischemia on clinical outcome has been proposed 
to be independent of other patient characteristics, includ- 
ing exercise and coronary angiographic f ndings (4610, 
12,15,19). The studies cited, however, lacked uniform crite- 
ria for evaluation ofambulatory ECG ischemia and did not 
incorporate clinical trial principles. Thus, no prospective 
randomized studies have compared different ischemia treat- 
ment strategies for their effects on adverse outcomes. 
Reported medical nd revascularization antianginal trials 
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were not designed to determine whether treating patients 
with asymptomatic &hernia or decreasing ischemia, or 
both, per se, decreases ri k of death or myocardial infarc- 
tion. Yet, some analyses uggest that revascularization 
might provide long-term benefit (8,20-25). One small non- 
randomized, study (26) suggested that medical treatment- 
related suppression f asymptomatic is bemia was associ- 
ated with a reduction in adverse outcomes. Despite the 
paucity of data, various treatments are frequently used, 
particularly coronary revascutarization, in the belief that 
alleviation of all ischemla will improve clinical outcome. 
Therefore, the question of whether suppression f ischemia, 
either symptomatic or asymptomatic, should be a goal of 
treatment, remains unanswered. 
s~y~~v~~ The primary objectives of
the Asymptomatic Ca mia Pilot (ACIP) study 
funded by the National Heart, Lung, and Blood Institute, are 
to assess the feasibility of recruiting patients meeting well 
defined criteria nd to evaluate whether different treatments 
will suppress i chemia (27). The ACIP study will provide 
estimates ofmortality and nonfatal cardiac events and will 
clarify issues important for a prognosis trial, such as whether 
entry criteria nd treatment regimens are implementable. 
Such a trial should include only patients with objective 
evidence of coronary artery disease of sufficient functional 
severity to result in transient ischemia. 
The exercise stress test is commonly used to evaluate 
transient ischemia and functional capacity. The ambulatory 
ECG records a continuous signal over days to indicate when 
ischemia occurs, its magnitude and duration and is the only 
test to provide information in the patient’s usual day-to-day 
environment. The ambulatory EGG has advantages in terms 
of convenience, costs and risks: however, disadvantages 
include wide day-today variability of ischemia within sub- 
nitoring (28-31). 
asymptomatic ischemia. 
tion between asymptom- 
atic ischemia and adverse outcome, the presence of ischemia 
was defined as at least one episode. An ischemia episode was 
defined as ST segment deviation 21 mm from baseline for 
21 mitt (32,33). This definition was adopted for the ACIP 
study. Initially, two or more episodes of ischemia with at 
least one asymptomatic episode were required to better 
detect treatment-associated reductions in ischemia. Analysis 
of early screening data revealed that changing the criterion 
to one episode of asymptomatic is hemia increased the 
number eligible with little loss of statistical power (34,35). 
&ions. Two combination drug regi- 
mens were chosen to maximize potential beneficial effects, 
minimize side effects and reflect current practice. Because 
drugs that decrease h art rate provide the most potent anti- 
ischemia actions, a beta-adrenergic blocking agent (atenolol 
[Tenormin, Zeneca Pharmaceuticals]) and a rate-slowing 
calcium antagonist (diltiazem [Cardizem SR. 
Dow]) were chosen as the initial componen 
ment combination. For the second drug, agents 
prominent vascular effect were chosen; the 
dropyridine calcium antagonist (nifed~pi~e 
Pfizer]) and a nitrate (isosorbide dinitrate [ 
Pharmaceuticals]). When 
ized to receive atenolol 
isosorbide dinitrate. Beta 
To test the ischemia suppression h 
assumed that anti-ischemic etTects are de 
tamed at the week I2 visit (84 to I82 days after random- 
ies. The Qrga~~zation 
of the AClP study is summarized in Appendix I. Potentially 
eligible patients had an ambulatory ECG, an ACHP protocol 
treadmill test, a IZlead ECG an a coronary angiogra 
Entry criteria ppear in Appendix 2, and d 
diagnostic tests appear in Appendix 3. 
consent was given before study entry. Treatment assign- 
ments were stratified by and within clinical unit by three 
revious coronary bypass urgery, no previous by- 
pass surgery and angina within 6 weeks of the qualifying 
ambulatory ECG (symptomatic stratum) and no previous 
bypass urgery and no angina within 6 weeks of the qualify- 
ing ambulatory ECG (asymptomatic stratum). Within each 
stratum, patients were randomly assigned to one of three 
strategies: I) angina-guided medical therapy (angina-guided 
strategy); 2)angina-guided plus ambulatory ECG ischemia- 
guided medical therapy (ischemia-guided strategy); and 
3) either percutaneous transluminal coronary angioplasty or
coronary bypass surgery (revascularization strategy) 
(Fig. I). Use of unblinded medication (which was always 
active) was permitted ineach strategy to control angina. 
AngiM- ed strategy. The goal of this strategy was 
angina control with an unblinded regimen of either atenolol 
plus nifedipine or diltiazem plus isosorbide dinitrate during 
the 1st 4 weeks. Adequate angina control was defined as 
fewer than three pisodes per week, easily controlled with 
sublingual nitroglycerin a d not interfering with usual activ- 
ities. 
Patients reporting angina at the randomization visit 
started unblinded medication step 1 (Table I), that is, drug 1, 
dose I (atenolol, 50 mg once a day, or diltiazem SR, 60 mg 
twice a day, based on regimen assignment). Patients who 
began taking drug 1 at the randomization visit were con- 
tacted by telephone 1 week fater. If adequate control had not 
been achieved, and there were no side effects, the dose of 
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Eligible patients 
Fi 
IS 
treatment strategies for rhe initiill 12 
weeks of the study. AECG = ambula- 
tory eiectrocar~io~~a~. 
Phase I 
(4 weeks) 
base 2 
(4 weeks) 
Phase 3 
(4 weeks) 
Revascuiarization 
4-week AECG for ischemia 
MildeJ 
medication 
(placebo) 
linded 
medication 
(active) 
Blinded 
medication 
(placebo) 
Blinded 
medication 
(attive) 
12-week AECG for ischemia (primary ouaome) 
drug 1 was increased (step 2). an telephone contact was 
made 1 week later to determine whether any additional 
adjustments were required. This process continued until 
angina control was achieved. The patient was then main- 
tained on this step of unblinded medication unless angina 
recurred and additionall medication was required. 
Patients whose angina couid not be controlled with max- 
imal unblinded medication were to receive additional un- 
Table 1. Medical Therapy Regimens ._ 
Regimen 
Step AtenoloUNifedipine Regimen* Diltiazem/lsosorbide Din&rate Regimen* 
I Atenolol, 50 mg qd (drug 1, dose I) Diltiazem SR, 60 mg bid (drug I, dose I) 
2 Atenolol, 100 mg qd (drug 1, dose 2) lP!iazem SR, !I0 mg bid (drug I, dose 2) 
3 Atenolol, IO0 mg qd (drug I, dose 2), and nifedipine XL, 30 mg qd Ddtiazem SR, !%I mg bid (drug I, dose 21, and ISDN, 20 mg bid 
(drug 2. dose I) (drug 2, dose I) 
4 Atenolol, 100 mg qd (drug 1, dose 2), and nifedipine XL, 60 mg qd Diltiazem SR, 90 mg bid (drug 1, dose 2). and ISDN, 40 mg bid 
(drug 2, dose 2) (drug 2, dose 2) 
*Assigned randomly unless one regimen was indicated or contraindicated. Supply of unblinded medications was provided for each enrolled palienl. A separate 
supply of blinded medications was provided for patients assigned to angina- or ischemia-guided strategies. lsosorbide dinitrate (ISDNI was to be given at 8 AM 
and 2 PM and diltiazem before the morning meal and at bedtime. bid = twice a day; qd = once a day: SR = slow release; XL = long acting. 
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Table 2. Summary of the Schedule of Procedures to Be Performed During the Qualifying Examinations and Follow-Up Visits 
Q@fYing 
Study Week 
R0cedUl.C Visit 2 4 6 8 IO 12 26 39 52 
coronery-Y X 
48-hombulatolyECG X x* x* X X X 
Exerthe tolerance test and rest ECG X X X X 
Angiaascmk X X X 
X X X X 
Tiie mcdiwii for symptoms X X X X X X X X 
Z”c4lt&lc evdualioa 
x 
X 
- and ischemia-gU&d strategy only. ECG = electrwudi 
blinded medication r other medication asdeemed appropri- 
ate, If the patient developed angina class III (Canadian 
Car&vasa&r Society Classification) despite maximal med- 
ical therapy, revascularization was considered. Patients who 
did not report annpina at entry followed the same visit 
‘na occurred at any time, assigned unblinded 
started using the same steps as in patients 
with angina t entry. 
Eligible patients requiring atenolol(50 mg once a day) or 
diltiazem (60 mg twice a day) were maintained on this 
background medication. Additional unblinded medication 
was used to I angina, as outlined earlier. 
l!Schemia- strategy. The goal of the ischemia- 
guided strategy was to eliminate ambulatory ECG ischemia 
after angina had been contmlled. Patients assigned toeither 
of the two medical strategies received blinded medication 
based on the reading at rile ambulatory ECG core laboratory 
of ambulatory ECGs performed at 4 and 8 weeks. Blinded 
medications were ither atenolol plus nifedipine ordiltiazem 
plus isosorbide dinitrate. For patients in the angina-guided 
strategy, blinded medication was placebo. For patients inthe 
ischemia-guided strategy, blinded medications were active 
(atenolol plus nifedipine or diltiazem plus isosorbide). If 
ischemic episodes were present, the clinical coordinating 
ceater notified the clinical unit that blinded medication 
should be started or increased, beginning with drug I, dose 1 
(step 1) for 1 week and, if there were no side effects, 
increased todose 2 (step 2). If a patient started on blinded 
medication at4 weeks also had ambulatory ECG ischemia at 
8 weeks, drug 2, dose 1 (step 3) was started and increased to
dose 2 (step 4) after 1 week if no side effects were reported. 
tion The goal of revascularization 
was to achieve corn ascularization when possible. 
Patients assigned toundergo revascularization were to have 
lasty or bypass urgery within 4 weeks (6 weeks 
oplasty) of the randomization visit. The revas- 
procedure was not assigned randomly but was 
determined by the study physician and the patient on the 
basis of coronary angiography performed within 2 months of 
revascuh&ation. Bypass urgery was preferred for 1) dif- 
fuse coronary disease with lesions >20 mm in length, 2) 
excessive tortuosity or angulation ofthe involved artery, 3) 
oc&M arteries, 4) inability to protect major side branches, 
and 5) lesions located so that a t vessel closure wool 
result in 
WdSGOll 
fied the 
Association guidelines (37). A sty was classified as 
success$~/ if residual stenoses dilated arteries were 
<50%, as measured by electromc c 
was alive and free of angina nd did not have procedure- 
related myocardial infarction or emergency b pass urgery. 
Therapy after evascula~~tion was based on local 
tice. As soon as feasible, medica 
to unbliaded active medication 
regimen (atenolol plus nifedipine or diltia 
bi at angina when nece 
outcome, study 
primary outcome was absence ofischemia on an ambulatory 
ECG recorded -12 weeks after entry. At this time drug 
titration should have been completed inthe medical groups, 
and stabilization was likely for those patients with revascu- 
larization. Patients who died or had myocardial infarction or 
nonprotocol revascularization before the Il-week ambula- 
tory ECG were counted as having ischemia. The follow-up 
visit schedule isoutlined in Table 2. 
Consistent with a pilot study, an overall significance level 
(alpha) of 0.10 was chosen. Three pairwise two-sided tests 
were planned, each at the 0.1013 =0.0333 significance level 
to compare the percent of patients with no ischemia on the 
1Zweek ambulatory ECG. Assuming 200 patients/group, 
and allowing for a 10% loss to follow-up, the effective 
number was 180 patients/group. if at least 30% of patients in
one group had ischemia t 12 weeks, 180 in each group 
provided at least 90% power to detect a50% reduction i the 
percent with ischemia at 12 weeks in the comparison group 
(i.e., 30% to 15%). The power to detect a 25% reduction i  
the percent of patients with ischemia (i.e., 39% to 22.5%) 
was only 30%. If at least 70% of patients in one group had 
ischemia, there was power HO% to detect a25% decrease in 
the other group. Thus, the ACIP study had adequate power 
to detect large relative differences in efficacy between treat- 
ments (35). 
Other outcome measures. Important secondary outcome 
variables included the following. 1) Ambulatory electmar- 
diogmphy: number and duration of ischsmic episodes/48 h; 
JAW Vol. 24. No. 1 
July t :I-10 
No. of 
Pts 
Quahfying visit AECG B ,959 
AECG eligible 952 
121 
Patient not consenting 6s 
CAD not suitable for revasculariaation 57 
Other exclusion criteria (Appendix 2) 35 
Personal physician not consenting 27 
not meeting eligibility 19 
tscellaneous reasons 10 
Totai Ineligible 334 
randomized to treatment strategy 618 
Medication r&men assignmem 
Physician assigned 255 
141 
Ii4 
Randomly assigned 363 
AIN I85 
D/I I78 
ABCG eligible = at least one asymptomatic episode on qualifying visit 
I-h ambulatory electrocardiogram; A/N = atenolol plus nifedipine regimen; 
CAD = coronary artery disease; D/I = dihiazem plus isosorbide dinitrate 
regimen; ETT = exercise treadmill test; Pts = patients. 
~~~~~~0~ of iscBepraia and rwaxi 
sustained ventricular tachycardia (con 
premature depolarizations at a rate ~1 
230 s); number of ven 
and number of rtms of 
(consecutive premature d polariz 
min lasting <30 s/48 
depression; time to ons 
depression; total numb exercise ECG leads; 
sum of ST segment depression i abnormal leads; occur- 
heart rate and blood pressure product at 
ic ST segment depression; exercise work 
Table 4. Screening and Recruitment Data by Site 
(Table 4). @era& 363 patients (59%) were randomized to 
receive ither dUazem plus isosorbide or atenolol pllus 
~jfedipi~e, ragging from 80% to 98% across ites (Table 4). 
aseline characteristics are s~rn~~zed by treat 
strategy and for all patients inTa 5 (85% men, 87% white; 
mean age 62 years, range 35 t ). In additron, 17% had 
previous a~g~~~lasty, nd 22% bad eit er previous angio- 
plasty or bypass urgery (or b 1. Ant~anginal medication 
was used in the 2 weeks before by 89% of patients, and 
53% took two or more drugs. Calcium antagonists were use 
in 57% of patients, beta-adreneqic blocking agents in 47% 
and long-acting nitrates in 37%. At randomization, 41% of 
AECG Eligible 
Qualifying Visit 
Clinical Unit AECG No. % 
OlRlniversity of Alabama 218 105 48 
OZlBaylor College of Medicine 231 87 38 
03Brigham anti Womens Hospital 139 77 55 
04KJniversity of Florida I98 70 35 
OS/Henny Ford Hospital 126 85 67 
06/Johns Hopkins University 118 73 62 
07/Monteriore Medical Center 217 84 39 
08iMontreal Heart Institute 157 92 59 
09/University of Ottawa 211 123 58 
BUSt. Bartholomew’s Hospital 175 76 43 
ll/St. Louis University 169 80 47 
Total: 1,959 952 49 
Data presented are number or percent of patients. Abbreviations as in Table 3. 
Randomized to 
Enrolled A/NorIlfl 
HO. % No. % 
61 58 57 93 
63 72 62 98 
60 78 6 IO 
58 83 38 66 
51 60 I7 33 
48 66 33 69 
44 52 24 55 
60 65 38 63 
69 56 34 49 
57 75 27 47 
47 59 27 57 
618 65 363 59 
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5. Baseline Characteristics 
- 
Treatment Strategy 
Angina Guided Ischemia Guided kvascularization 
(n = 204) (n = 202) (1: = 212) 
No. % No. I No. % 
All 
(n = 61181 
-____p 
NO. % 
Age WI 61 f 8 62 f 8 64 r9 62 + 8 
260 yr 124 61 129 64 130 61 383 62 
Male gender 182 89 171 85 171 81 524 85 
White 178 87 171 85 I87 88 536 87 
Nanwhile 26 13 31 I5 25 12 82 I3 
in SQ wk of enlry 
On QV E’ff or olher stress lest 
With ischemic episode on QV Ai332 
Any of the above 
History 
Previous MI 
Diabetes 
Heart failure 
Peripheral vascular disease* 
Hypertension 
Currem smoker 
Ever smoked* 
Previous PTCA 
Revious CABG 
Previous FTCA andlor CABG 
Physical examination 
Systolic pressure (mm Kg) 
Diastolic pressure (mm Kg) 
Heart rate (beats/min) 
Stenosis rS6% 
I vessel 
2 vessel 
3 vessel 
Bjection fraclion 
120 59 124 61 I23 58 367 59 
100 49 II5 57 IO8 51 321 52 
I6 x 28 14 ?I SO 65 II 
143 70 I48 73 148 70 439 71 
19 39 78 39 91 43 248 40 
29 14 37 I8 40 I9 906 17 
7 3 4 2 7 3 I8 3 
8 4 27 13 13 6 48 8 
64 31 81 40 86 41 231 37 
38 19 32 I6 25 I2 9s I5 
152 75 131 65 121 57 404 65 
38 19 33 16 31 I5 102 17 
I2 6 14 7 II 5 37 6 
49 24 44 22 41 19 134 22 
138 + 18 MO f 21 I39 + 19 I39 + I9 
79 d IO ilO+ 10 79rt IQ 79 + IO 
692 12 7Or II 69% 12 69% 12 
46 23 51 2s 51 24 148 24 
70 34 71 35 87 41 228 37 
88 43 80 40 74 35 242 39 
.W :o 64% 
2&t’& 
Not available 
Rest Il.lead ECG 
Normal 
Q waves 
ST depression 
T wave abnormalities 
0 0 4 ! 4 2 8 I 
I8 9 19 IO I9 IO 56 IO 
82 43 88 46 a5 44 255 44 
90 47 RO 42 a7 45 257 45 
14 II I7 42 
II3 5s 97 48 YY 47 309 50 
21 10 27 I3 29 I4 77 12 
46 23 54 27 50 24 150 24 
57 28 62 31 74 35 193 31 
l p = 0.001. otherwise no significant differences. Data presented are mean value f SD or number and percent of patients. AECG = ambulatory 
eh?ctroEardiogram; CABG = coronary artery ~YDBSS surnerery: BTf = exercise test; MI = myocardial infarction; PTCA = percutaneous transluminal coronary 
an&&sty; QV = qualifying visit. _ 
patients reported no angina in the previous 6weeks; how- 
ever, the majority (71%) had angina during the 6 weeks 
before ntry, during the exercise test or during the qualifying 
visit ambulatory ECG associated with ischemia. Fatients in 
the three treatment strategies were comparable with respect 
to baseline characteristics, with two exceptions. More pa- 
tients in the ischemia-guided strategy group than in the other 
two strategy groups had peripheral vascular disease. A 
smaller percent of patients in the revascularization strategy 
group reported a history c* smoking. Only 10% of the 
patients in each group were not taking antianginal drugs. 
Physical findings and findings on qualifying aqiograms 
are also summarized bytreatment in Table 5. Most patients 
had multivessel coronary obstructions and good left ventric- 
ular function (mean ejection fraction 61%). The median time 
from angiography to study entry was 20 days (range 0to 57 
months). 
All patients had ST segment depression i at least one 
JAW Vol. 24, No. 1 
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trial was designed to determine which 
ment strategy wo~~~ de better suppression f isc 
at 12 weeks. Longer how-up will determine whether sup- 
tveness ofdifferent 
treatment s rategies. ~nfo~atio~ collected uring the ACIB 
study will be vital to planning and co~d~cti~~ a prognosis 
trial. Key issues are assessment of screening procedures for 
patients with asymptomatic ischemia, adverse ffects of 
anti-ischemic regimens and mortality and morbidity. These 
issues are pivotal in protocol development fora larger trial to 
assess treatment effects nosis. 
The recruitment goal atients was met 1 year after 
all clinical units initia recruitment. The percent of 
screeued patients who were ambulatory KG eligible varied 
considerably by clinical unit (35% to 67%). In planning a
prognosis tria: it should be anticipated that about three 
patients st be screened for each patient enrolled. This 
estimate es not take into account he effort to identify 
patients o be screened. Almost 60% of patients were eligible 
to be randomized to either of the two medical regimens, but 
this also varied widely by clinical unit (10% to 98%). 
Characteristics of patients eligible for this randomization 
were very similar to those of all patients entered (data not 
iderable evidence for 
ah three treatments have a favorable 
ut outcome results have not bee 
anadian Cardiovascu- 
exercise test and either two 
ipine combined with atenolol (41). The primary out- 
variable was ambulatory ECG ischemia t 9 weeks. 
Thr: data from these trials will become available shortly and, 
along with the AC1 study, should provide very important 
informatjo~ needed plan a major outcome trial. 
The Multicenter Silent yocardial Ischemia ( 
Research Group recently reported on 936 patients who were 
in clinically stable condition 1 to 6 months after myocardiat 
infarction or unstable angina (42). The investigators con- 
cluded that neither silent nor symptomatic ischemia was 
useful in identifying patients at increased risk for subsequent 
events. The cohort of patients included in this registry were 
selected from an initial group of 8,552 patients admitted, of
whom 2,096 patients met eligibility requirements a  1 to 6 
months after hospital contact. The enrolled cohort had a 
relatively ow occurrence ofcardiac death or nonfatal myo- 
cardial infarction at 2 years (7 5%). This registry bad many 
shortcomings, the most important ofwhich were that <3% 
of patients were identified as high risk, and only 7% bad 
ambulatory ECG ischemia. Thus, the power to detect any 
differences between low and high risk patients was quite 
low. 
ary. Design considerations and baseline character- 
istics for the ACIP study are presented. The ACE study has 
several unique aspects not addressed by other trials, and it 
will provide detailed information on the potential for con- 
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ducting a trial to assess the effect of control of all ischemia 
on prognosis. 
ACIP Clinical Units 
: W. J. Uqters.’ K. Al-Shaihi. V. 
Rittncr, D. Cox. K. Hanna, M. Lawson, R. Lev 
e, H. Taylor, V. Varma. G. Duke. L. Levson, 
, F. Atkins. S. Brewer, 
: C. Pratt.* C. Habib, N. Kieiman, J. 
Rnberra. II. Stein. M. Francis. T. Hollo. L. Miller. Q. Morris. R. _ ._ _ _. ._. - ~. .  
i-R. Frafcr. w’. Fris 
r. M. Greenbe~, H. Wirsc 
Fo~~r.8~~. S. Furia. K. 
. Bourossa.’ R.Banan. 1. DYrda. 
J. L&&&e, Y. LeCkrc. C. Pelletkr. C. Faille. A. Poitras. J. TideI. 
: R. F. Davies: M. Rird. 
arauis. T. Ruddv. L. Lammee. 
. 
8. R. Chainnan.* G. Williams. F. Aauirre. P. Bierreaaard. E. Caraccioln. G. 
Kaiser, M. Kern. L. McBride, D. Miller. H. &tm~n. R. Wiens. S. Byen, 
P. Flynn. 
ACIP Core Laboratories and Clinical 
Coordinating Centers 
Kaufffann. G. L. Knauerud. D. Sheps. G. Sopko, 
ix 2 -. 
Entry Criteria for the ACIP Study 
mite&~ Patients of any age with all of the following 
were included in the study: I) on the ambu!atory electrocardio8ram 
*Denotes Principal Investigator. 
(EC@. at least one episode of asy tomatic ischemia; 21 on AC1 
orotocol treadmill test (or arm e rise test or stress perfusion 
imaging if patient could not use ~readrni~~~, ECG evidence of 
ischemia. 31 coronary artery disease (e50% diameter narrowing) on 
an angio ithin 53 years of ambMlat0~~ ECG screening or 5 
years if ient bad triple-vessel disease; 4) revascula~za~le 
obstructions; 5) left ventricular ~~octio~ that does not exclude 
revascula~~at~o~; and 6) willing to give informed consent to partic- 
s were excluded for any of the folow- 
e require a negative 
in 4 weeks: 3) coro- 
nary angioplasty within 6 ~~ont~~s; 41 coronal bypass surgery ~v~t~i~ 
angina at entry define 
min ~ss~iat~d with 
I mV in two co~t~~~~us 
ive effort angina iacreas in f~eq~~e~cy imd d~~~~t~ 
nsive to rne~ic~tio~ or erring with less exertion, 
,&l admission: or cl Canadian ~~rdiov~scMla~ Society 
class IV; 6) significant ~o~cardi~c illness that might contribute to 
death within 5 years; 7) siR~ifican~ nonc~ro~ary cardiac disorders 
that would require su~ery or increase mortality: 8) congestive heart 
failure of Nm York Heart Ass~iation functional class Ill or IV 
with medical therapy; 9) inadequate an 
) cofltraindicatio~ to both 
I I) currently faking anti-is 
afely discontinued for 2 to 3 
myocardial imfarction patients 
with either background atenolol(50 mg once a day) or slow-~&ase 
diltiazem ‘i mg twice a day): 121 coronary artery disease not 
amenable to rev~~,c~lar~zat~o~; 13) left main coronary a 
z%FZ diameter narrowing: 14) ECG abnormalities t 
with ambulator) ECG ST segment analysis: IS) abno 
ST se8meot (c.8.. depression or elevation 20.1 
isoelectric line in lead considered for arnb~~latory ECG rno~~to~n~, 
or change I mV with tural euvcrsl; I61 need for digitalis: 
17) investi onal new d witlti days of qualifying ambulatory 
ECG; 181 participation in competing protocol or unreliable or 
geographically inaccessible for follow-us. 
pendix 3 
ACIP Study Ekgibility Tests 
Ambulatory electrocardiographic monitoring. All ambulatory 
electrocardiographic monitoring sessions consist of two 24-h record- 
ings using a two-channel AM ambulatory ECG cassette device with 
automatic calibration. Leads monirored are those demonstrating 
greatest ST segment deviation during baseline exercise test, and the 
same leads are used for each recording session. Electrodes are 
placed with adequate skin preparation and skin resistance measured 
using an ohm meter. Before recording, a test strip is inspected using 
a cable connected from the ambulatory ECG recorder to a conven- 
tional l24ead KG recorder. Specific criteria used to ensure inter- 
pretable ST segment activity are normal sinus rhythm, QRS dura- 
tion 50.10 s (except for right bundle branch block with isoelectric 
ST segments in lateral precordial leads) and no significant Q wave in 
the monitored lead. The R wave height in lateral precordial leads 
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if ST §e~~~~t deviation 5 1 .O mm occurs with 
postural maneuvers Man 
Bus, supine and ~y~~rve~~ 
Bschemic-type ST &vi 
or dow~s~opj~~ ST segment depression 2 1 .sU mm below the isoelec- 
tric line ctttd 2 1 .O mm below the “has 
t eleva~~~~ e I. m above 
he “Daseliae” segment 
as ST segment deviation last 
point at which S’ff segment deviatiun first satisfies i>chemic 
criteria previously noted. Episo 
ST segment deviation no Ionger satisfies is 
wi 
ctric linef. Episode doratio 
isoelectric line. After an ischcnric cpisodc, e ?il’ segment value 
must return to the baseline ViilW pre ixhennic epkodu fur 
min before new ST ~e~~~e~~t viation is considered a new 
is episode. 
the standard protocol. Criteria for ischemia-r&t 
require a change from the baseline ECG at rest. An ischrmic 
response was defined as I) J point and ST segment level 80 ms after 
the J point (ST 80) depression = I .O mm. ST segment horizontal or 
downsloping <I mV/s; or 21 ST 80 depression 2 I.5 mm and ST 
segment upsloping > I mV/s. 
~~~i~yi~~ cwmiwy a~R~~~~a . Coronary anaiun~y and venrric- 
ular function had to be suitable for revascularkation. with a zW% 
(by electronic calipers in one view) diameter narrowing in one or 
more major coronary artery and film adequate to co&m revascu- 
larizatlrvn eligibility. eligibility required obstructive coronary artery 
disease on the basis of an angiogram obtained within the past 3 
years, provided that the patient did not have a clinical evaat (t.g., 
~yoca~dial infarction. hospital admission for unstable angina, rc- 
vascularization) after the angiogram. When this occurred, a second 
angiogram was required. For those patients with three-vessel dis- 
ease, an angiogram performed within 5 years was aCCCptdbk, 
provided that there was no intercurrent clinical event and left 
ventricular function suitable for revascularization was confirmed by 
radionuclide ventriculography or echocardiography. 
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